Morita Shohei, Mochizuki Youhei, Kondo Takahiro, Matsuda Yasuyoshi, Ohmori Takahiro, Yoshimura Aritada, Fukushima Ryuji
Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Faculty of Veterinary Medicine, Okayama University of Science, Okayama, Japan.
Front Vet Sci. 2025 Apr 30;12:1570349. doi: 10.3389/fvets.2025.1570349. eCollection 2025.
In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension.
This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (≥14 μg/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure ≥160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg).
Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups.
It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.
在犬类中,慢性肾病(CKD)常与高血压相关。氨氯地平用于治疗犬类高血压,我们预计给予氨氯地平可能会改善犬类的肾功能。然而,氨氯地平对犬类肾功能的影响尚不清楚。因此,本研究评估了因持续性SDMA水平升高而被诊断为CKD且仅因任何原因接受氨氯地平治疗的宠物犬在给予氨氯地平前后对称二甲基精氨酸(SDMA)水平的变化。我们还进行了一项比较研究,以探讨这些患有CKD的犬是否患有高血压,其SDMA变化是否存在差异。
本研究采用回顾性设计。研究对象为SDMA持续升高(≥14μg/dL)、被诊断为CKD且接受氨氯地平治疗的宠物犬。收集了品种、性别和年龄等概况数据,以及氨氯地平给药前后的血液化学检测、血压、心率和超声心动图数据。该研究纳入了45只犬,其中20只为高血压犬(HT:收缩压≥160mmHg),25只为非高血压犬(非HT:收缩压<160mmHg)。
在HT组和非HT组中,给药后平均SDMA均显著低于给药前。此外,我们发现所有接受氨氯地平治疗的CKD犬的心输出量(CO)均增加。血压测量显示,HT组和非HT组的血压均下降。
据信,氨氯地平给药导致的CO增加会提高肾小球滤过率,这可能导致SDMA水平下降。根据收缩压的下降速率,我们认为氨氯地平可能会使高血压水平较高的患者血压下降幅度更大。在本研究中,我们表明,无论犬是否患有高血压,给予氨氯地平均可改善CKD犬的SDMA水平。我们还表明,氨氯地平可安全用于治疗血压正常的犬。